Clinical trials: Light Chain (AL) Amyloidosis
Light Chain (AL) Amyloidosis
Daratumumab for Patients With Light Chain Amyloidosis
This is a prospective, single-center study exploratory clinical trial, aim to exploring the efficacy and safety of daratumumab in patients with AL amyloidosis, patients were divided into three groups: one group received long-term…
- Trial name
- NCT06376214
- Testing
- Dratumumab / Hyaluronidase Injection [Darzalex Faspro], Pomalidomide 4 MG, autologous stem cell transplantation (ASCT)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Nanjing University School of Medicine
AL Amyloidosis
Daratumumab for the Treatment of Patients With AL Amyloidosis
Participants with AL Amyloidosis will receive the drug daratumumab by IV infusion once weekly for two months, then every 2 weeks for four months, then once each month.
- Trial name
- NCT02841033
- Testing
- daratumumab
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Boston Medical Center
Amyloidosis; Systemic
Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients
This is a single arm, open label study designed to evaluate the safety and efficacy of propylene glycol-free melphalan hydrochloride in patients with AL amyloidosis.
- Trial name
- NCT02994784
- Testing
- Propylene Glycol-Free Melphalan Hydrochloride
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Boston Medical Center
AL Amyloidosis
Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis
This is a phase II study in patients with newly diagnosed Mayo stage IIIB immunoglobulin light-chain (AL) Amyloidosis to evaluate the efficacy and safety of teclistamab
- Trial name
- NCT07079423
- Testing
- Teclistamab (Tec)
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Peking Union Medical College Hospital
Cardiac Amyloidosis, AL Amyloidosis
Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
This is an open-label, multi-center pivotal Phase 3 study to visually and quantitatively assess PET images obtained after single application of 300 MBq [18F]florbetaben and PET scanning of patients with suspected cardiac…
- Conditions
- Cardiac Amyloidosis, AL Amyloidosis, ATTR Amyloidosis
- Trial name
- CArdiag (NCT05184088)
- Testing
- [18F]florbetaben
- Where
- 14 sites in United States, Germany and 2 more
- Volunteers
- 244 people
- Sponsor
- Lantheus Germany GmbH
Amyloidosis; Systemic, AL Amyloidosis
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
Achievement of complete hematologic response (CHR) is vital for systemic AL amyloidosis. Currently, the CHR rate of daratumumab, bortezomib, and dexamethasone (DBD) is close to 60%.
- Trial name
- NCT06192979
- Testing
- Daratumumab, Bortezomib, Dexamethasone
- Where
- 7 sites in China
- Volunteers
- 41 people
- Sponsor
- Jin Lu, MD
Amyloidosis
Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis
The drugs dexamethasone and bortezomib are both FDA-approved for the treatment of multiple myeloma, a disease very similar to amyloidosis. However, they are currently investigational for the treatment of amyloidosis.
- Trial name
- NCT01083316
- Testing
- Bortezomib, Dexamethasone, Melphalan
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Boston Medical Center
Amyloidosis
Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis
This is a phase 1/2 open-label, dose-escalation study investigating single-agent therapy with VELCADE in patients with previously treated systemic AL-amyloidosis who require further treatment.
- Trial name
- NCT00298766
- Testing
- VELCADE
- Where
- 4 sites in United States
- Volunteers
- 70 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Relapsed/Refractory AL Amyloidosis
Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis
This is a Phase 1b open-label, multicenter, non-randomized study of GC012F, a CD19/BCMA dual CAR T cell therapy, in adult participants with relapsed/refractory AL amyloidosis.
- Trial name
- NCT07250269
- Testing
- GC012F Injection
- Where
- 9 sites in China
- Volunteers
- 9 people
- Sponsor
- Gracell Biotechnologies (Shanghai) Co., Ltd.
AL Amyloidosis, Plasma Cell Dyscrasia
Autologous Stem Cell Transplantation for Patients With AL Amyloidosis
This study mainly evaluated the efficacy and safety of autologous stem cell transplantation for the treatment of AL amyloidosis, the role of induction and maintenance therapy in autologous stem cell transplantation, and the…
- Trial name
- NCT04210791
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Nanjing University School of Medicine
Immunoglobulin Light Amyloidosis Cardiomyopathy
Clinical Study for AL-CM
In this study, patients diagnosed with Al-CM were selected to observe the effect of treatment and conduct long-term follow-up.
- Trial name
- NCT04924998
- Testing
- current treatment of AL-CM
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Multiple Myeloma
S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis
RATIONALE: Chemotherapy plus interferon alfa may be effective for primary systemic amyloidosis. PURPOSE: Phase II trial to study the effectiveness of dexamethasone plus interferon alfa in treating patients who have primary…
- Trial name
- NCT00002849
- Testing
- recombinant interferon alfa, dexamethasone
- Where
- 40 sites in United States
- Volunteers
- 93 people
- Sponsor
- SWOG Cancer Research Network
Primary Amyloidosis
Radioimmunoimaging of AL Amyloidosis
The purpose of the study is to determine the capability of a radiolabeled amyloid-reactive monoclonal antibody to document the presence and distribution of amyloid deposits by PET/CT imaging in patients with AL amyloidosis.
- Trial name
- NCT00807872
- Testing
- 124I-labeled monoclonal antibody Mu 11-1F4
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Tennessee
AL Amyloidosis
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
The purpose of this study is assess safety, safest dose, and effectiveness of venetoclax in combination with dexamethasone in participants with t(11;14) positive relapsed (comes back) or refractory (did not get better) light…
- Trial name
- NCT05451771
- Testing
- Venetoclax Oral Tablet, 200 mg, FISH assay, Venetoclax Oral Tablet, 400 mg
- Where
- 4 sites in United States
- Volunteers
- 53 people
- Sponsor
- Columbia University
Amorphous, Eosinophilic, and Acellular Deposit, Constipation
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
This phase II trial studies how well isatuximab works in treating patients with primary amyloidosis that has come back or does not respond to treatment.
- Conditions
- Amorphous, Eosinophilic, and Acellular Deposit, Constipation, Diarrhea, Early Satiety
- Trial name
- NCT03499808
- Testing
- Isatuximab, Laboratory Biomarker Analysis
- Where
- 345 sites in United States
- Volunteers
- 43 people
- Sponsor
- SWOG Cancer Research Network
AL Amyloidosis, POEMS Syndrome
One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS
By detailed sequence analysis and subsequent biophysical characterization of prototypic light chains, this project aims to identify sequence fingerprints in IGLV1-44 light chains leading to AL amyloidosis and POEMS syndrome.
- Conditions
- AL Amyloidosis, POEMS Syndrome, Multiple Myeloma
- Trial name
- ALPS (NCT07448935)
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
AL Amyloidosis
Allo SCT in Amyloidosis Non-interventional Study
Light-chain (AL-) amyloidosis is a very rare monoclonal plasma cell disorder with poor prognosis. Rarity of disease has precluded performance of randomized controlled trials comparing various possible treatment modalities.
- Trial name
- NCT02257905
- Where
- 4 sites in France, Germany and 1 more
- Volunteers
- 14 people
- Sponsor
- European Society for Blood and Marrow Transplantation
Multiple Myeloma, AL Amyloidosis
COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies
To determine whether protective antibody levels increase after booster dosing with the Moderna COVID-19 vaccine in patients diagnosed with Hematologic Malignancies who have low antibody levels after a prior first vaccination with…
- Conditions
- Multiple Myeloma, AL Amyloidosis, Chronic Lymphocytic Leukemia
- Trial name
- NCT05028374
- Testing
- A single "booster" dose of the Moderna mRNA COVID-19 vaccine
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
AL Amyloidosis
Study in Subjects With Light Chain (AL) Amyloidosis
The objective of this study is to evaluate the long-term safety and efficacy of NEOD001 in subjects with AL amyloidosis who have completed Study NEOD001-201.
- Trial name
- NCT03154047
- Testing
- NEOD001
- Where
- 34 sites in United States, Australia and 8 more
- Volunteers
- 80 people
- Sponsor
- Prothena Biosciences Ltd.
Amyloidosis, Systemic Light Chain Amyloidosis
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
This is a dose finding study to evaluate the safety and determine the maximum tolerated dose of carfilzomib in patients with previously treated systemic light-chain amyloidosis.
- Trial name
- NCT01789242
- Testing
- Carfilzomib, Dexamethasone
- Where
- 10 sites in United States
- Volunteers
- 32 people
- Sponsor
- Criterium, Inc.